Press Release
02.10.2026

Luther successfully advises Sanofi on the approval of a 400-million-euro state aid package for a new insulin plant in Frankfurt-Höchst

The European Commission has approved a German state aid package of 400 million euros in favour of Sanofi-Aventis Deutschland GmbH. The funds are being provided by the Federal Government, the State of Hesse and the City of Frankfurt and form a key part of the financing for the multi-billion investment in a state-of-the-art new insulin plant in Frankfurt-Höchst.
Ein verschwommener Konferenzraum mit mehreren Personen in formeller Kleidung, die im Gespräch sind. Im Vordergrund steht ein Tisch mit mehreren Laptoptaschen und Dokumenten. Große Fenster im Hintergrund lassen Tageslicht herein.
Contents

The Luther team was led by Dr Helmut Janssen, LL.M. (Partner, State Aid Law, Brussels) and Prof Dr Christian Burholt, LL.M. (Partner, Co-Head of Luther’s Healthcare & Life Sciences Industry Group). The team included Martin Lawall, LL.M. (Senior Associate, State Aid Law, Brussels), Lasse Langfeldt, LL.M. (Senior Associate, State Aid Law, Brussels) and Ulf-Dieter Pape (Partner, Public Law/Administrative Law, Hanover).

About Sanofi:

Sanofi is a research-based biopharmaceutical company committed to improving people’s lives and responsible growth. The company applies its in-depth understanding of the immune system to provide life-saving vaccines and treatment options to millions of people worldwide. Millions more could benefit from its innovative pipeline. Sanofi tackles the most pressing challenges of our time in healthcare, the environment and society.

Sanofi is listed on the EURONEXT stock exchange under the ticker symbol SAN and on NASDAQ under the ticker symbol SNY.


Contents

Newsroom